Education
About Us
Working with TipRanks
Follow Us
Stoke Therapeutics (STOK)
:STOK
Total Valuation
Stoke Therapeutics has a market cap or net worth of $940.87M. The enterprise value is $418.08M.
Market Cap$940.87M
Enterprise Value$418.08M
Share Statistics
Stoke Therapeutics has 54,797,417 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding54,797,417
Owned by Insiders39.04%
Owned by Institutions0.99%
Financial Efficiency
Stoke Therapeutics’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -42.93%.
Return on Equity (ROE)-0.39
Return on Assets (ROA)-0.33
Return on Invested Capital (ROIC)-42.93%
Return on Capital Employed (ROCE)-0.44
Revenue Per Employee285.59K
Profits Per Employee-695.16K
Employee Count128
Asset Turnover0.13
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Stoke Therapeutics is 21.6. Stoke Therapeutics’s PEG ratio is ―.
PE Ratio21.6
PS Ratio―
PB Ratio―
Price to Fair Value2.60
Price to FCF―
Price to Operating Cash Flow16.26
PEG Ratio―
Income Statement
In the last 12 months, Stoke Therapeutics had revenue of 36.55M and earned -88.98M in profits. Earnings per share was -1.65.
Revenue36.55M
Gross Profit36.55M
Operating Income-101.37M
Pretax Income-88.98M
Net Income-88.98M
EBITDA-99.19M
Earnings Per Share (EPS)-1.65
Cash Flow
In the last 12 months, operating cash flow was 61.60M and capital expenditures -451.00K, giving a free cash flow of 61.15M billion.
Operating Cash Flow61.60M
Free Cash Flow61.15M
Free Cash Flow per Share1.12
Dividends & Yields
Stoke Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.00
52-Week Price Change24.47%
50-Day Moving Average12.53
200-Day Moving Average10.66
Relative Strength Index (RSI)83.33
Average Volume (3m)777.05K
Important Dates
Stoke Therapeutics upcoming earnings date is Nov 11, 2025, Before Open (Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateNov 11, 2025
Ex-Dividend Date―
Financial Position
Stoke Therapeutics as a current ratio of 5.81, with Debt / Equity ratio of 0.00%
Current Ratio5.81
Quick Ratio5.81
Debt to Market Cap<0.01
Net Debt to EBITDA1.27
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Stoke Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Stoke Therapeutics EV to EBITDA ratio is -4.74, with an EV/FCF ratio of -5.40.
EV to Sales12.86
EV to EBITDA-4.74
EV to Free Cash Flow-5.40
EV to Operating Cash Flow-5.41
Balance Sheet
Stoke Therapeutics has $247.71M in cash and marketable securities with $2.30M in debt, giving a net cash position of -$245.41M billion.
Cash & Marketable Securities$247.71M
Total Debt$2.30M
Net Cash-$245.41M
Net Cash Per Share-$4.48
Tangible Book Value Per Share$4.24
Margins
Gross margin is 93.09%, with operating margin of -277.31%, and net profit margin of -243.42%.
Gross Margin93.09%
Operating Margin-277.31%
Pretax Margin-243.42%
Net Profit Margin-243.42%
EBITDA Margin-271.36%
EBIT Margin-277.31%
Analyst Forecast
The average price target for Stoke Therapeutics is $23.93, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$23.93
Price Target Upside31.41% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast1218.82%
EPS Growth Forecast―